U.S. Markets closed

Biotech Giant Celgene Tops First-Quarter Estimates As Bristol Buyout Looms

ALLISON GATLIN
Biotech Giant Celgene Tops First-Quarter Estimates As Bristol Buyout Looms

Celgene earnings of $2.55 per share on $4.03 billion in revenue topped the consensus Thursday. But Celgene stock dipped a fraction in late trading.